CAR-T therapy for advanced multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell treatment (IASO104) for people with multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this therapy can help control the disease with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have tried at least 3 treatments for multiple myeloma (including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody) unless your cancer is resistant to those medicines.
- Your disease must be getting worse or have come back within 12 months of your last therapy, or your last therapy was a CAR-T cell treatment.
- You must have measurable signs of myeloma (like high M-protein in blood or urine, or many plasma cells in bone marrow).
- You must be active enough to do light housework or desk work (ECOG 0-1) and have a life expectancy of at least 12 weeks.
- You must have good organ function (kidneys, liver, heart, lungs, and blood counts) and use effective birth control for a year after the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells boosted with a protein called IL-15) for people with multiple myeloma or plasma cell leukemia that has not responded to standard treatments or has come back. The goal is to see if these enhanced cells can better fight the cancer.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins on myeloma cells: GPRC5D and CD19. It is for people whose myeloma has come back or stopped responding to at least 3 prior treatments. The goal is to see if this treatment is safe and helps control the disease.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
Hear when a new Relapsed/Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.